XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

NCT00127933 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

157

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: capecitabine [Xeloda]
DRUG: Taxotere
DRUG: Herceptin (HER2-neu positive patients only)
DRUG: capecitabine [Xeloda]
DRUG: Taxotere

Sponsor

Hoffmann-La Roche